Amplifon's shares rose 4.8% post-earnings, reflecting stronger-than-expected organic growth and margin expansion across all regions, supported by disciplined portfolio optimization and successful Fit4Growth execution.
- Organic revenue growth accelerated to 4.7% in Q2, well above the estimated 2.5%-3% global market growth.
- Adjusted EBITDA margin improved by 90 basis points year-over-year, driven by operating leverage and cost efficiencies from Fit4Growth.
- Fit4Growth negatively impacted revenues by approximately 3.5% due to clinic closures and portfolio pruning, but contributed positively to profitability.
- Americas organic growth was a standout at 6%, offsetting negative impacts from managed care agreement termination and FX headwinds.
- Free cash flow surged nearly €30 million (+70%) in H1 2026, reinforcing financial flexibility amid ongoing investments in brand and store experience enhancements.
Community Discussion